HArmonyCa Nodules: Hybrid HA + CaHA Lumps, Half-Reversible

A lot of people arrive like this: they had HArmonyCa, liked the result, and then a few months later started feeling firm little lumps at certain points on the face. They go back to where it was done, and the answer is often "that's rare, just massage it."

Let me say the honest part first. HArmonyCa's published nodule rate really is low, and that deserves to be said plainly. The issue isn't that it lumps easily. The issue is that it's a hybrid material, and once a lump does form, the logic for handling it is nothing like handling plain hyaluronic acid (HA). You assume "it has HA in it, so it can be dissolved" — and that's only half true.

What HArmonyCa actually is, and why "dual action"

HArmonyCa is a hybrid injectable from Allergan that mixes two things together: a crosslinked hyaluronic acid gel (20 mg/mL) acting as the carrier, with microspheres of CaHA (calcium hydroxyapatite, the same material in Radiesse) suspended in it, roughly 25 to 45 microns across, plus 0.3% lidocaine for comfort. By weight, the CaHA microspheres make up about 55.7% — a number that surprises most people, because it means the part that can be dissolved is actually the smaller half.

The selling point is "two jobs in one injection." The HA does the immediate filling and lifting, so you see something the day you walk out. The CaHA microspheres slowly stimulate your own collagen, which carries the support over the following months to a year or two. The design itself is clever; the manufacturer calls the mechanism DART, its dual-action technology.

And the root of the lump problem lives right there too. Anything that stimulates collagen is, by definition, asking your body to react to a foreign object. Most people react just right. A few react too much, the collagen grows in excess and unevenly, and that becomes a nodule.

Key point: Any material that stimulates collagen carries some chance of an over-reaction that turns into a lump. HArmonyCa's nodule risk is counted as "low" — but low is not zero, and it certainly doesn't mean a lump will be easy to deal with if it happens.

Where can it be injected, and how long does it last?

In Taiwan, where this clinic practises, the approved use is to add volume to the soft tissue of the midface, lateral face and lower face, injected into the deep dermis, subcutaneous layer or onto the periosteum (licence MOHW-MD(I)-038192). The approved package insert lists the glabella, the eye area, the lips and the area around the lips as places it must not be injected, along with the epidermis and superficial dermis. The post-marketing study abroad injected mainly the cheeks and jawline (Gritti et al. 2025).

The insert gives the duration as about 12 to 18 months, with retreatment generally after about a year. In that 140-person prospective study, the responder rate was 82.8% at month 1 and then declined to 65.9% by month 12 (Gritti et al. 2025; most authors are employees of AbbVie, the manufacturer). Put simply, about two in three people still showed the effect at one year.

Who shouldn't have it?

The approved insert's contraindications include pregnancy or breastfeeding, age under 18, known allergy to any component (including lidocaine), infection or inflammation at or near the treatment site, a tendency to keloids or hypertrophic scars, autoimmune disease, herpes, and allergy or contraindication to steroids.

Two lines matter most for anyone coming for revision. The insert lists "injection into an area containing foreign material" as a contraindication, and it states that safety and effectiveness have not been evaluated in patients who have already been treated with other filler implants. If that area has had another filler before, especially a permanent one, you are in exactly the group this product has no safety data for.

Who makes HArmonyCa, and why the exact product name matters later

This looks like a footnote about branding. It isn't — it's the detail that most often sends a lump down the wrong treatment path, so it gets its own section.

HArmonyCa is made by Allergan Aesthetics, an AbbVie company, and the underlying hybrid technology came out of Luminera in Israel. It has been rolled out market by market, which means the name on your consent form isn't always the name people say out loud. In Taiwan, for example, the TFDA-registered name is Heng-Ti-Jia, while clinics and patients almost always use the nickname Mei-Shen-Zhen (美神針). Same syringe, different labels.

Why does that matter to you? Because months later, when you can feel a lump and you go to have it looked at, what was injected is the fact that decides how it should be handled. If all you can say is "I had some kind of lifting filler," and the doctor assumes plain HA, you get the classic mistake: attacking something that is half not hyaluronic acid with the method for hyaluronic acid. Bring the product name, the lot number or the receipt from the original treatment — that tells a doctor far more than describing where you were injected.

It also helps to know where HArmonyCa sits among the products it gets compared with: Radiesse is pure CaHA, Ellansé is PCL, Sculptra is PLLA. They all share the same basic idea — persuade your own collagen to grow — but they differ in carrier and in how reversible they are, and that difference is exactly where the path forks once a lump appears. The brand-to-ingredient table across markets is in the filler encyclopedia, and this product's material page is HArmonyCa (HA + CaHA hybrid).

The other side of "dual action": how lumps form, and why the delayed risk is underrated

Start with the published numbers, because they shape how you should read the risk. A 2024 retrospective study in PRS Global Open (PMID 38348461, 403 participants) reported implant-site nodules in roughly 1.2% to 2.1% of cases, most of them noninflammatory and early-onset within two months, looking more like material accumulation. A separate 2024 real-world retrospective (PMID 39360597, 129 patients) put nodules at 0.8%.

That sounds reassuring. There are three limits you should know about, though.

First, the follow-up in these studies is still fairly short, and several are industry-related or industry-funded. For a product this new, the truly delayed nodules can take many months or a year-plus to surface, and current data hasn't captured that tail yet. Second, at the level of the whole CaHA-type biostimulator class, delayed nodules are a documented phenomenon, not a surprise. So "looks low right now" and "definitely safe long term" are two different statements. Third, change the definition and the number changes. A 2025 post-marketing prospective study of 140 people counted treatment-related "injection site mass" instead, at 10.7%, with 7 mass events still unresolved when the study ended (PMID 40948024). The paper doesn't define "mass"; it may be broader than "nodule" and may include material you can feel for a while after treatment, so it can't be set directly against the 1–2% above. It does tell you that feeling something after injection is not unusual, and the approved insert itself warns that the filler may be palpable for some time after treatment.

What I see in clinic tends to be the person who landed inside that one or two percent. To the statistics she's a rare case. To herself it's a hundred percent.

What does "HArmonyCa gone wrong" usually mean?

Mostly one of these: nodules or lumps you can feel or see; material that has moved somewhere it shouldn't be (the insert calls it migration); left-right asymmetry; or redness and swelling that keep coming back long after injection. The insert's list of less common adverse events also includes protrusion, induration, fistula, infection, persistent nodules, granuloma, and the vascular complications of necrosis and blindness. Those vascular events are emergencies and a different matter from a lump that develops slowly.

Dr. Ta-Ju Liu: "Where it was injected also changes how problems look. In a place that moves all the time, like the chin, a firmer, shape-holding material such as HArmonyCa often goes wrong not as a round lump but as a point, an odd forward jut, or asymmetry. Then the goal of revision is to smooth and even out the proportions of the profile, not to take it all out."

Dr. Ta-Ju Liu: "Low odds don't mean it's easy to take out if it does happen."

The "half-reversible" trap of hybrid materials: HA dissolves, CaHA does not

Hyaluronidase dissolves the HA in HArmonyCa. It does not dissolve the CaHA microspheres, or the collagen they stimulated. This is the part I most want you to remember.

A lot of patient education out there says: "HArmonyCa has HA in it, so if you're unhappy you can dissolve it with hyaluronidase." That sentence is only partly right. Hyaluronidase is an enzyme made specifically to break down hyaluronic acid, and the only thing it can dissolve is the HA portion. The CaHA microspheres are not hyaluronic acid, so hyaluronidase does nothing to them; and the collagen your body has already grown around the CaHA is even further from anything the enzyme can touch.

In other words, after you dissolve the HA carrier, the hard core is often still sitting there — and by weight, what stays behind is the larger share.

Dr. Ta-Ju Liu: "People often tell me, 'I had the dissolving injection, it got a bit smaller, but the hard part is still there.' That isn't because the injection wasn't enough. What dissolved was the hyaluronic acid half; what's left is the CaHA and the collagen it stimulated."

Dr. Ta-Ju Liu: "With any composite, 'it contains HA' does not mean 'the whole thing dissolves.'"

So a hybrid material creates an illusion of "reversible." What's reversible is the HA. What isn't reversible is the actual problem. This runs along the same line as how we handle plain Radiesse (CaHA) complications, which you can read alongside this in Radiesse complications and calcified lumps; and for why dissolver injections so often do nothing, 7 reasons hyaluronidase fails goes deeper.

Why "let's try steroid first" is often not a good answer

When a lump appears, a common first move is to inject steroid into the area to suppress inflammation. It sounds reasonable. In practice it's a decision that's easy to regret.

Steroid may settle an inflammatory nodule, but against a HArmonyCa lump whose core is stimulated collagen, it runs into an awkward fact: steroid causes tissue to atrophy. It won't necessarily shrink that hard core, yet it will atrophy the normal fat and collagen sitting next to the lump first. And its effect is ongoing, not a one-and-done — after you stop, the tissue keeps drifting toward a depression for a while longer.

I've seen too many faces where the lump stood firm while the area beside it caved in. What started as a bump problem becomes a bump that's still there, plus a new hollow — harder to fix than the original.

Dr. Ta-Ju Liu: "That injection did not treat the problem. It treated the tissue next to the problem. And the tissue that atrophied is precisely what you need if you later have to address that nodule."

Key point: With a collagen-driven lump, the thing to fear isn't "it didn't work" but "the normal tissue next to it collapsed first." If steroid is used at all, the dose, the location and the number of sessions have to be very conservative, and you should think through whether atrophy can be reversed before you start. I lay this out bluntly in steroid injection and the risk of tissue atrophy.

If you've already been advised to have steroid, I'd ask you not to rush into treating the whole face. Better to test a small area first and watch the response than to treat a large patch at once — if the reaction is atrophy, doing the whole face together costs far too much.

From watching to minimally invasive removal: a decision ladder for lumps

Not every lump needs an immediate intervention. There's an order to handling them, from light to heavy, and the point is knowing which rung you're on and when to step down.

1. Type it before you treat it. Use ultrasound to see clearly whether this lump is inflammatory, noninflammatory, or an already-formed fibrous nodule. Get the type wrong and the whole path that follows goes wrong.
2. Early, mild, noninflammatory ones get time and conservative observation first. Some early material accumulation settles on its own, and this is not the stage to start injecting things to "fix" it.
3. Ones that keep growing or repeatedly inflame may, after an in-person assessment, call for intralesional medication or gentle physical release — but every step has to weigh the cost to the surrounding tissue.
4. Stable, stubborn fibrous nodules with a clear palpable border are where ultrasound-guided single-pinhole physical extraction earns its place. Under real-time imaging you locate that core and take the CaHA microspheres and the overgrown fibrous tissue out through one pinhole, instead of adding more material or chemically chasing something that won't dissolve.

Why is physical removal especially central for a hybrid? Because of what we covered above: CaHA and collagen, the two things that are the real core of the lump, can't be dissolved by any drug. The reversible HA leaves on its own, and what stays behind is the part you have to take out. That's why we position minimally invasive removal as the last resort for hybrid collagen-stimulator lumps, not the first step.

Dr. Ta-Ju Liu: "At the removal stage, what I care about isn't just whether it comes out but whether the area is even afterwards. The hard core is often joined to the fibrous tissue that grew around it: take too little and the lump is still there; take too much and the area next to it caves in. So the extent has to be seen clearly on ultrasound first, to take no more and no less than needed."

What happens if you leave it alone? Early material accumulation can settle by itself, which is why the second rung is time. For plain Radiesse, one review puts complete resorption of CaHA at about 2.5 years (McCarthy et al. 2024; all five authors have financial ties to Radiesse's maker); whether the CaHA in HArmonyCa behaves the same way hasn't been studied. Lumps that keep growing or keep flaring are a different story and go back to the decision ladder above. Separately, the approved insert itself says some adverse events may need surgical intervention (such as draining a haematoma or seroma), and that the implant must be removed if inflammation or infection develops.

After removal: recovery time and scarring

After single-pinhole removal: the pinhole is small, but this is an extraction, so swelling and bruising are expected. Swelling and bruising usually settle in about 2–3 weeks, and the roughly 2 mm pinhole heals in about 2 weeks, after which it is usually barely visible (the same explanation is in our single-pinhole extraction explainer). The final result takes about 3 months, varying from person to person, so the ups and downs in the first few weeks aren't the final picture. Whether a dent is left depends on whether the extent was marked precisely beforehand and only what needed to come out was taken.

To understand the causes and treatment framework for this whole class of collagen-stimulator lumps, see the full collagen-stimulator lumps overview.

Before you inject, and after: what you can do

If you're still considering HArmonyCa: choose a doctor with experience who will assess with ultrasound, and keep the dose conservative and staged rather than filling a lot at once. Over-injection is the single biggest amplifier of nodule risk, and that holds for every collagen stimulator.

If you've already had it and are starting to feel lumps: the approved insert tells patients to massage the area if a nodule appears, and that fits the early phase, when material has simply pooled after injection. If it's still there after a while, is getting firmer, or turns red, stop kneading it yourself and don't rush to have something injected either. Note when each one appeared, where it is, how firm it is, whether it's red or swollen, and find a doctor who will look properly with ultrasound and tell you honestly which lump should wait and which should come out. With a hybrid lump, the worst mistake is using the method for HA to attack a problem that isn't HA.

I tell patients very plainly: HArmonyCa isn't a bad product, and its nodule rate genuinely isn't high. But if you turn out to be one of the few, remember it's a hybrid — the half that dissolves was never the problem; the half that doesn't is. See it clearly and treat it the right way, and you won't drag a small lump into an uneven face.

Frequently Asked Questions

What is HArmonyCa, and what's actually in it?

It's a hybrid injectable: a crosslinked hyaluronic acid gel (20 mg/mL) carrying microspheres of CaHA (calcium hydroxyapatite, the same material as Radiesse), about 25 to 45 microns across, plus 0.3% lidocaine for comfort. By weight, the CaHA microspheres account for roughly 55.7%. The HA does the filling and lifting you can see the day it's injected; the CaHA microspheres slowly stimulate your own collagen over the following months. So it is a filler and a collagen stimulator at the same time — and that dual identity is exactly what makes a lump harder to deal with later, because only the carrier can be touched by an enzyme.

Are the different market names the same product, and why should I tell my doctor exactly what I had?

Yes, they're the same product. HArmonyCa comes from Allergan Aesthetics (AbbVie), with technology originating at Luminera in Israel, and it is registered under different names in different markets — in Taiwan the official TFDA name is Heng-Ti-Jia, though it's usually called Mei-Shen-Zhen locally. Whichever name you heard, say clearly which product was injected when you seek help for a lump, and bring the product name or lot number if you can. A hybrid material and a plain HA filler are handled by completely different logic, and getting that wrong sends the whole plan in the wrong direction.

What are the side effects of HArmonyCa?

The common short-term ones are swelling, bruising and tenderness after injection, which usually settle within one to two weeks. The one that matters most is nodules and lumps: published data puts them at roughly 0.8% to 2.1%, most of them early-onset, noninflammatory nodules appearing within two months of injection; a prospective study using the broader definition "injection site mass" reported 10.7%. Other possibilities include migration, left-right asymmetry, and recurrent local inflammation. The most serious but rare event is vascular occlusion, a risk shared by all injectable fillers rather than something specific to this product. If a lump only shows up two or three months later, or keeps flaring red and swollen, treat it as a delayed reaction worth a proper assessment — not something to massage away.

Can HArmonyCa lumps be dissolved with hyaluronidase?

Only the HA carrier can. Hyaluronidase works on hyaluronic acid alone; the CaHA microspheres and the collagen your body has already grown around them are not its targets. So once the HA portion is dissolved, the hard core is often still sitting exactly where it was — which is why so many people say the dissolver injection changed nothing.

When do HArmonyCa lumps usually appear?

The published data clusters in the early-onset window, within about two months of injection. But at the level of the whole CaHA-type biostimulator class, delayed nodules are a documented phenomenon, and HArmonyCa has been on the market for a relatively short time, so the long tail hasn't fully surfaced yet. A lump you first feel six months or more after treatment deserves to be taken just as seriously — "the studies say it's rare" is not a reason to leave it alone.

Where can HArmonyCa be injected, and how long does it last?

The approved use in Taiwan is adding volume to the soft tissue of the midface, lateral face and lower face, placed in the deep dermis, subcutaneous layer or onto the periosteum; the glabella, eye area, lips and around the lips are listed as places not to inject. The insert gives a duration of about 12 to 18 months, and in a 140-person prospective study the responder rate fell from 82.8% at month 1 to 65.9% at month 12.

Who shouldn't have HArmonyCa?

The approved insert's contraindications include pregnancy or breastfeeding, age under 18, allergy to any component or to lidocaine, infection or inflammation at the injection site, a tendency to keloids, autoimmune disease, herpes, and injection into an area containing foreign material. It also states that it hasn't been evaluated in people already treated with other fillers, so if that area has had filler before, say so before anything is injected.

How long is recovery after a HArmonyCa lump is removed, and will it scar?

Swelling and bruising are expected and usually settle in about 2–3 weeks. The roughly 2 mm pinhole heals in about 2 weeks and is then usually barely visible. The final result takes about 3 months, varying from person to person.

How is HArmonyCa different from Radiesse, Ellansé and Sculptra?

Radiesse is pure CaHA, Ellansé is PCL and Sculptra is PLLA — all single-material collagen stimulators. HArmonyCa is a hybrid of HA and CaHA. The difference lies in the carrier and in reversibility: with HArmonyCa, only the HA half can be addressed with hyaluronidase, and the part that remains behaves much more like plain Radiesse when it comes to treatment.

References

1. Taiwan Food and Drug Administration. HArmonyCa Lidocaine – Injectable Facial Implant, licence MOHW-MD(I)-038192, approved Chinese package insert.
2. Braz A, Colucci L, Macedo de Oliveira L, et al. A Retrospective Analysis of Safety in Participants Treated with a Hybrid Hyaluronic Acid and Calcium Hydroxyapatite Filler. Plast Reconstr Surg Glob Open. 2024;12(2):e5622. PMID: 38348461.
3. Proietti I, Spagnoli A, Favaroni A, et al. HArmonyCa hybrid filler to restore connective tissue: An Italian real-life retrospective study. J Cosmet Dermatol. 2024;23(12):3883–3892. PMID: 39360597.
4. Gritti A, Salomon M, Elmaleh L, et al. A Prospective, Open-Label, Post Marketing Study of the Safety and Effectiveness of a Hyaluronic Acid and Calcium Hydroxyapatite Hybrid Injectable. J Cosmet Dermatol. 2025;24(9):e70430. PMID: 40948024. (140 participants, 12-month follow-up; most authors employed by AbbVie.)
5. McCarthy AD, van Loghem J, Martinez KA, et al. A Structured Approach for Treating Calcium Hydroxylapatite Focal Accumulations. Aesthet Surg J. 2024;44(8):869–879. PMID: 38366791. (Plain CaHA only; all authors have financial ties to Merz.)

If you can feel a lump you're unsure about, or you've been treated and the result wasn't good, you're welcome to come in for an assessment with Dr. Ta-Ju Liu. We'll look with ultrasound first, then decide the next step together.